- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00179374
Improving Diabetes Outcomes With Activity, Nutrition and Medication
Improving Diabetes Medication Adherence and Outcomes
This study has the following specific aims:
- A tailored telephone intervention will significantly improve medication adherence compared to a standard care intervention.
- A tailored telephone intervention will significantly improve metabolic control measured by HbA1c compared to a standard care intervention 2a) We will explore ways to link behavior change for medication adherence with lifestyle modification for diet and physical activity.
- To conduct cost evaluations for the telephone intervention vs. standard care.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Metabolic control of type 2 diabetes and prevention of its complications are related to management of blood glucose and other factors. Medication and lifestyle modifications are integral to most self-management plans; however, adherence remains a great challenge. Many patients have abnormal HbA1c, blood pressure and lipid values, and are at greater risk for complications. This study is to evaluate the effectiveness and costs of a tailored, telephone intervention to promote adherence in middle-aged and older adults with type-2 diabetes who are members of a union/employer-sponsored health benefit plan. The target population includes English- and Spanish-speaking individuals from the health plan database.
This study has the following specific aims:
- A tailored telephone intervention will significantly improve medication adherence compared to a standard care intervention.
- A tailored telephone intervention will significantly improve metabolic control measured by HbA1c compared to a standard care intervention 2a) We will explore ways to link behavior change for medication adherence with lifestyle modification for diet and physical activity.
- To conduct cost evaluations for the telephone intervention vs. standard care. The study design is a randomized, controlled intervention trial with masking; the individual is the unit of sampling, assignment and analysis. After eligibility is assessed and consent is obtained by telephone, patients will be randomized to either the telephone intervention or standard are. Study outcomes will be medication adherence as measured from pharmacy records and metabolic control (HbA1c). A total of 556 patients with type 2 diabetes wil be randomized, which will provide 80% power to detect a statistically significant difference in HbA1c of at least 0.3%, and over 95% power to detect a difference in filled prescriptions. Telephone surveys will provide data on self-care behaviors including diet and exercise, risk perceptions, and depressive symptoms. Cost data will be collected using standardized methods. Study results will inform implementation of practical, nurse-managed interventions to improve medication adherence and metabolic control in diverse, middle-aged and older, type 2 diabetes patients, while linking changes in medication adherence to lifestyle modification for diet and physical activity.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
New York
-
Bronx, New York, Förenta staterna, 10461
- Albert Einstein College Of Medicine
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Type 2 diabetes
- Taking oral diabetes medication
- At least 40 years old
- In a union-sponsored health plan with full medication coverage for at least a year
- Able to understand English or Spanish
- Informed consent
Exclusion Criteria:
- Currently in a diabetes education program
- Will lose health care eligibility within a year
- Unable to receive phone calls or mail
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: 1
Tailored telephone intervention plus mailed print educational materials
|
Tailored telephone intervention to promote metabolic control of diabetes
|
Aktiv komparator: 2
print intervention with no telephone component
|
diabetes educational materials by mail
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Medication adherence
Tidsram: 1 year
|
1 year
|
Metabolic control (measured by HbA1c)
Tidsram: 1 year
|
1 year
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Changes in self-care behaviors including diet and exercise
Tidsram: 1 year
|
1 year
|
Cost evaluations
Tidsram: 1 year
|
1 year
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Elizabeth A Walker, DNSc, RN, Albert Einstein College Of Medicine
- Huvudutredare: Hillel W Cohen, DrPH, MPH, Albert Einstein College Of Medicine
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2003-068
- R18DK062038 (U.S.S. NIH-anslag/kontrakt)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Diabetes mellitus, typ 2
-
Mathias Ried-LarsenOkändDiabetes mellitus, typ 2 | Typ 2-diabetes mellitus | Diabetes typ 2 | Typ 2 diabetes mellitusDanmark
-
SanofiAvslutadTyp 1-diabetes mellitus-typ 2-diabetes mellitusUngern, Ryska Federationen, Tyskland, Polen, Japan, Förenta staterna, Finland
-
Hanmi Pharmaceutical Company LimitedOkändTyp 2 diabetes mellitus | Typ 1 diabetes mellitusFörenta staterna
-
Caroline M KistorpRigshospitalet, Denmark; Herlev and Gentofte Hospital; Danish Heart FoundationAvslutadTyp 2 diabetes mellitusDanmark
-
TheracosAvslutadTyp 2 diabetes mellitusFörenta staterna
-
Biocon LimitedAvslutadJämförelse av insulin tregopil (IN-105) med insulin aspart hos patienter med typ 2-diabetes mellitusTyp 2 diabetes mellitusIndien
-
Chong Kun Dang PharmaceuticalOkändTyp 2 diabetes mellitusKorea, Republiken av
-
PegBio Co., Ltd.AvslutadTyp 2 diabetes mellitusKina
-
Chong Kun Dang PharmaceuticalAvslutadTyp 2 diabetes mellitusKorea, Republiken av
-
Daiichi Sankyo Co., Ltd.AvslutadTyp 2 diabetes mellitusJapan
Kliniska prövningar på Tailored telephone intervention of education
-
Duke UniversityNational Institute of Mental Health (NIMH)AvslutadSchizofrenispektrum och andra psykotiska störningar | Psykiska störningar, allvarligaTanzania
-
Thomas Jefferson UniversityRekryteringProstatakarcinomFörenta staterna
-
Institute of Technology, SligoAvslutad
-
Institute of Technology, SligoAvslutad
-
Thomas Jefferson UniversityAvslutadHematopoetisk och lymfoid cellneoplasma | Malign fast neoplasmaFörenta staterna
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityHar inte rekryterat ännu
-
NYU Langone HealthIndragen
-
Centers for Disease Control and PreventionAvslutadHIV-infektioner | Hepatit CFörenta staterna
-
Universiti Putra MalaysiaAvslutadDiabetes typ 2 | Diet, hälsosam | Hälsokunskap, attityder, praktikIrak
-
The University of Texas at ArlingtonUniversity of Texas Southwestern Medical CenterAvslutad